What is the present valuation and projected CAGR of the cardiac amyloidosis market?
The cardiac amyloidosis market size has grown strongly in recent years. It will grow from $5.26 billion in 2024 to $5.75 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to rising prevalence of amyloidosis-related conditions, rising prevalence of genetic mutations, increasing awareness, increasing prevalence of transthyretin amyloidosis cases, and rising geriatric population.
The cardiac amyloidosis market size is expected to see strong growth in the next few years. It will grow to $8.10 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to increasing diagnosis rates, government support and initiatives, increased diagnosis rates, rising prevalence of genetic mutations, and patient assistance programs. Major trends in the forecast period include development of new therapies such as vulrisiran, expanding research in gene therapy, a focus on precision medicine, advancements in diagnostic technologies, and the development of novel therapies.
Get Your Free Sample of The Global Cardiac Amyloidosis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp
What key drivers have fueled the cardiac amyloidosis market’s development over the years?
The increasing geriatric population is expected to propel the growth of the cardiac amyloidosis market going forward. The geriatric population refers to older adults, typically aged 65 and above, who may require specialized healthcare and support due to aging-related changes. The geriatric population is increasing due to rising life expectancy, advancements in healthcare, and declining birth rates. The increasing geriatric population raises the prevalence of cardiac amyloidosis, as aging is a major risk factor for amyloid protein accumulation in the heart. For instance, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Therefore, the increasing geriatric population will propel the cardiac amyloidosis market.
What is the segmentation for the cardiac amyloidosis market?
The cardiac amyloidosis market covered in this report is segmented –
1) By Product Type: Light Chain Amyloidosis, Transthyretin Amyloidosis
2) By Treatment: Chemotherapy, Surgery, Supportive Care, Stem Cell Transplant, Targeted Therapy
3) By End-User: Hospitals, Ambulatory Surgical Centres, Clinics
Subsegments:
1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis, Primary Light Chain Amyloidosis, Secondary Light Chain Amyloidosis
2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm), Wild-type Transthyretin Amyloidosis (ATTRwt)
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report
Who are the most influential companies in the cardiac amyloidosis market?
Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Alexion Pharmaceuticals Inc., Dr. Reddy’s Laboratories, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Amylyx Pharmaceuticals, Neurimmune AG, SOM Biotech, Oncopeptides, Attralus Inc., Eidos Therapeutics.
What are the top industry trends projected to impact the cardiac amyloidosis market?
Major companies operating in the cardiac amyloidosis market are focusing on technological innovations, such as artificial intelligence (AI)-based software-only diagnostic tools, to enhance early detection and improve clinical outcomes for patients with this underdiagnosed disease. An artificial intelligence (AI)-based, software-only medical device that detects cardiac amyloidosis is a diagnostic tool that uses artificial intelligence to analyze echocardiographic images and identify signs of the disease without requiring additional hardware or extensive clinical data. For instance, in November 2024, Ultromics Ltd., a UK-based health technology company, secured FDA clearance for EchoGo Amyloidosis, an AI-powered clinical tool for early cardiac amyloidosis detection. It is the first device in the FDA’s Total Product Lifecycle Advisory Program (TAP) to receive marketing authorization. Using artificial intelligence, EchoGo Amyloidosis analyzes echocardiograms to detect the disease from a single clip, addressing the urgent need for earlier diagnosis before it progresses unnoticed.
What are the major regional insights for the cardiac amyloidosis market, and which region holds the top position?
North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Cardiac Amyloidosis Market Report 2025 Offer?
The cardiac amyloidosis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Cardiac amyloidosis is a condition where abnormal amyloid protein deposits in the heart tissue, leading to stiffening and impaired function. This results in heart failure, arrhythmias, and other cardiovascular complications. Early diagnosis and treatment are crucial to managing symptoms and slowing disease progression.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21128
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
